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Background: Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is
prognostic for survival following surgery or radiotherapy and predicts benefit from hypoxia modification of radiotherapy. Adding mitomycin C
(MMC) and 5-fluorouracil (5-FU) chemotherapy to radiotherapy improved locoregional control (LRC) compared to radiotherapy alone in the
BC2001 trial. We hypothesised that tumour necrosis would not predict benefit for the addition of MMC and 5-FU to radiotherapy, but would be
prognostic.
Methods: Diagnostic tumour samples were available from 230 BC2001 patients. Tumour necrosis was scored on whole-tissue sections as absent
or present, and its predictive and prognostic significance explored using Cox proportional hazards models. Survival estimates were obtained by
Kaplan–Meier methods.
Results: Tumour necrosis was present in 88/230 (38%) samples. Two-year LRC estimates were 71% (95% CI 61–79%) for the MMC/5-FU
chemoradiotherapy group and 49% (95% CI 38–59%) for the radiotherapy alone group. When analysed by tumour necrosis status, the adjusted
hazard ratios (HR) for MMC/5-FU vs. no chemotherapy were 0.46 (95% CI: 0.12–0.99; P¼ 0.05, necrosis present) and 0.55 (95% CI: 0.31–0.98; P¼ 0.04,
necrosis absent). Multivariable analysis of prognosis for LRC by the presence vs. absence of necrosis yielded a HR¼ 0.89 (95% CI 0.55–1.44,
P¼ 0.65). There was no significant association for necrosis as a predictive or prognostic factor with respect to overall survival.
Conclusions: Tumour necrosis was neither predictive nor prognostic, and therefore MMC/5-FU is an appropriate radiotherapy-sensitising
treatment in MIBC independent of necrosis status.
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Patients with muscle invasive bladder cancer (MIBC) undergo a
radical cystectomy to remove the whole bladder or organ
preserving tri-modality treatment. The most common tri-modality
treatment involves a transurethral resection of the bladder
(TURBT) to remove gross tumour from the bladder wall followed
by radiotherapy with concurrent chemotherapy with or without
prior neoadjuvant chemotherapy. Combining radiation with
chemotherapy gives comparable rates of disease-specific and
overall survival (OS) to cystectomy (approximately 30–50% at 5
years; Hoskin et al, 2010; Choudhury et al, 2011; James et al, 2012;
Booth et al, 2014). Two large phase III randomised control trials
from the UK showed the benefit of giving either chemotherapy
(BC2001) or hypoxia-modifying therapy (BCON) with radiation.
The BC2001 study showed that the addition of mitomycin
C (MMC) and 5-fluorouracil (5-FU) to radiotherapy improved
locoregional control; at two years LRC estimates were 67% (95%
CI: 59 to 74) in the chemoradiotherapy group and 54% (95% CI:
46–62) in the radiotherapy group (HR 0.68, 95% CI, 0.48–0.96;
P¼ 0.03). The BCON study showed adding carbogen and
nicotinamide (CON) to radiotherapy increased 3-year OS rates
by 13% (Hoskin et al, 2010). With increasing options for treating
the disease, there is a need to predict which patients are likely to
benefit from tri-modality treatment and to which radiation
modifying combination. Although there are a number of accepted
prognostic factors for MIBC such as stage, grade and performance
status of the patient, there are as yet no predictive factors, which
can be used to select patients who are likely to benefit from the
different treatment regimens.
Necrosis can be seen histopathologically using haematoxylin and
eosin (H&E) staining and is likely to result from periods of low
oxygen tension resulting in cell death. Thus, necrosis may be a
surrogate for extreme hypoxia within tumours. Hypoxia is an adverse
prognostic factor in MIBC (Hoskin et al, 2003; Palit et al, 2005; Ord
et al, 2007; Hunter et al, 2014) and necrosis was associated with a
poor outcome in three independent studies (Ord et al, 2007; Eustace
et al, 2013; Soave et al, 2015). The presence of frank necrosis was also
shown to correlate with the expression of hypoxia-associated markers
and to predict benefit from hypoxia modification in patients enroled
in the BCON trial (Eustace et al, 2013).
The BC2001 study used MMC and 5-FU as radio-sensitising
agents. MMC is the prototype bioreductive agent, that is, a pro-
drug that is selectively metabolised in hypoxic cells to a cytotoxic
compound (McKeown et al, 2007). However, although it has some
bioreductive activation and selective toxicity towards hypoxic cells
in vitro, it is a weak bioreductive agent in vivo because hypoxia-
independent toxicity occurs at a dose level lower than that required
for hypoxia-dependent toxicity (McKeown et al, 2007). Therefore,
we hypothesised that the presence of necrosis in tumour samples
from BC2001 patients would not predict benefit for the addition of
MMC and 5-FU to radiotherapy, but would be prognostic. The
study reported here aimed to test this hypothesis.
PATIENTS AND METHODS
Patients and samples. A retrospective cohort study was carried
out using diagnostic tumour samples from patients enroled in the
BC2001 phase III trial (ISRCTN68324339, CRUK/01/004). BC2001
has been described in detail elsewhere (James et al, 2012; Huddart
et al, 2013). In brief, 360 patients with MIBC suitable for radical
treatment with radiotherapy were randomised to either radio-
therapy alone (n¼ 178) or with concurrent MMC (12mgm 2 on
D1) and 5-FU (500mgm 2 on D1-5 and D16–20, n¼ 182).
Patients were treated with one of two radiotherapy regimens in
standard use in the UK, either 64Gy in 32 fractions over 6.5 weeks
or 55Gy in 20 fractions over 4 weeks.
Formalin-fixed and paraffin-embedded (FFPE) tissue samples
from the TURBT were available for central histological assessment
from 245 patients diagnosed with MIBC between May 2001 and
December 2007. Data from 230 were analysed (Figure 1). Approval
for the necrosis study was obtained from the North West Greater
Manchester East Ethics Committee (09/H1013/24). Informed
consent for sample collection and analysis were obtained
prospectively from each patient as part of the main trial. REMARK
guidelines for reporting tumour marker prognostic studies were
followed (McShane et al., 2005).
Histopathology. Methods have been described previously in detail
(Eustace et al, 2013). In summary, a single 4 mm whole-tissue
section from the FFPE block was obtained for H&E staining. As in
other standard solid tumour histopathological reporting, tissue-
hypoxia-related coagulative necrosis, characterised by loss of tissue
architecture, increased eosinophilia and nuclear breakdown, was
scored by a consultant urohistopathologist as absent vs present.
Supplementary Figure S1 is a selection of histological images
illustrating necrosis. The pathologist was blinded to the treatment
received by the patient and to the clinical outcome data.
Statistical analyses. Analyses were undertaken for locoregional
control (LRC) and OS. LRC was the primary endpoint of the trial
and was measured from the time of randomisation to recurrence in
pelvic nodes or bladder (muscle invasive or non-muscle invasive),
with data censored at the first sign of metastasis (if this occurred
X30 days before locoregional failure), a second primary cancer or
death. Median follow-up for the 230 patients in this cohort was
71.3 months.
Heterogeneity in the treatment effect according to the tumour
necrosis status was first explored graphically by Kaplan–Meier
curves comparing treatment by necrosis status, and log-rank tests
for each comparison reported. The predictive significance of
necrosis was formally addressed by a test for interaction, first in a
Cox proportional hazards model including treatment, necrosis
status and their interaction (unadjusted analysis), and then
including known prognostic factors (in the literature or relevant
in the main BC2001 trial (adjusted analysis). These factors were:
sex, age, WHO status, stage, tumour size (only for LRC),
haemoglobin (only for OS), residual mass after resection and
presence of Cis. The prognostic significance of necrosis was
similarly explored by Kaplan–Meier curves comparing necrosis
status and fitting Cox models with necrosis and treatment, but
without the interaction term.
Hazard ratios (HR) and their 95% confidence intervals are
reported for all variables in the final models. The association
between necrosis status and other prognostic factors was explored
by w2-tests for categorical factors and t-test for continuous. The
proportional hazards assumption of the Cox model was tested with
the use of Schoenfeld residuals and found to hold for all three
survival end points. All statistical analyses were performed using
Stata (version 13.1, Stata Corp, College Station, TX, USA).
RESULTS
Tumour samples from 230 of the 360 patients participating in the
BC2001 chemoradiotherapy randomisation were available for
analysis: 121 out of 230 (52.6%) patients received chemoradiother-
apy and 109 out of 230 (47.5%) patients received radiotherapy
alone (Figure 1). Baseline characteristics (Table 1) were generally
balanced between the two randomisation groups within the main
study, but patients in this analysis set undergoing radiotherapy
alone tended to have had a higher percentage of incomplete
resection (P¼ 0.03) and larger tumours (P¼ 0.07). Necrosis was
present in 88 out of 230 (38%) of the tumours, and did not differ
between treatment groups (P¼ 0.82). The baseline characteristics
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of the necrosis cohort broadly represented the patients of the
BC2001 trial (Supplementary Table S1) but, in comparison with
the 130 patients with no tissue available for analysis, the 230
patient cohort had significantly more T2 disease (P¼ 0.001),
higher levels of haemoglobin (P¼ 0.02) and a higher percentage
received 64Gy/32F (Po0.001). Supplementary Figure 2 shows
there were no significant differences in LRC (P¼ 0.76) and OS
(P¼ 0.16) for patients with or without tissue available.
Two-year LRC estimates were 71% (95% CI 61–79%) for the
chemoradiotherapy group and 49% (95% CI 38–59%) for the
radiotherapy group. The presence of necrosis did not predict
benefit from the addition of chemotherapy to radiotherapy.
Figure 2A and B shows that concomitant chemotherapy improved
LRC in patients with or without tumour necrosis. In 142 patients
where necrosis was absent, 2-year LRC was 67.6% for the
chemoradiotherapy group and 50.8% for radiotherapy alone
(HR¼ 0.60, 95% CI 0.35–1.03, log-rank P¼ 0.07). In 88 patients
with tumour necrosis, two-year LRC was 75.7% for the
chemoradiotherapy group and 45.8% for radiotherapy alone
(HR¼ 0.43, 95% CI 0.20–0.91, log-rank P¼ 0.03). There was no
interaction between treatment and necrosis in either univariable
(P¼ 0.47 unadjusted) or multivariable (Table 2, predictive model,
P¼ 0.71 adjusted) analyses. Table 2 also summarises the results of
the univariable and multivariable analyses of possible prognostic
factors for LRC in the 230 patients. Necrosis had no prognostic
significance for LRC in either univariable (P¼ 0.50) or multi-
variable (P¼ 0.65) analyses (Table 2, Figure 3A). Significant
adverse prognostic factors in the combined cohort were advanced
stage, a residual mass after resection and lack of chemotherapy.
The presence of necrosis also had no prognostic significance when
the analysis was restricted to patients receiving radiotherapy alone
(Figure 3B).
Five-year OS rates were 44.4% (95% CI 35–53.3%) for the
chemoradiotherapy group and 35.1% (95% CI 25.7–44.5%) for the
radiotherapy group (log-rank test P¼ 0.32). There was a trend to a
benefit in OS for adding chemotherapy to radiotherapy in patients
with rather than without tumour necrosis (Figure 2C and D)
though this did not reach statistical significance. In 142 patients
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Figure 1. The CONSORT diagram showing the flow of patients through the study.
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Table 1. Baseline characteristics
Total Chemoradiotherapy Radiotherapy
230 (100.0%) 121 (100.0%) 109 (100.0%) P-valuea
Sex
Male 183 (79.6%) 97 (80.2%) 86 (78.9%) 0.81
Female 47 (20.4%) 24 (19.8%) 23 (21.1%)
Age (years)
N 230 121 109 0.97
Median (Q25–Q75) 72.1 (65.7–76.4) 72.1 (66–76.4) 71.9 (65.7–76.2)
Min–Max 40.2–87 40.2–87 49–85.9
WHO performance status
0 146 (63.5%) 77 (63.6%) 69 (63.3%) 0.33
1 79 (34.3%) 43 (35.5%) 36 (33.0%)
2 5 (2.2%) 1 (0.8%) 4 (3.7%)
Pathological stage—primary tumour
1b 1 (0.4%) 0 (0.0%) 1 (0.9%) 0.72
2 202 (87.8%) 107 (88.4%) 95 (87.2%)
3a 8 (3.5%) 3 (2.5%) 5 (4.6%)
3b 10 (4.3%) 6 (5.0%) 4 (3.7%)
4a 9 (3.9%) 5 (4.1%) 4 (3.7%)
Grade primary tumour
2 26 (11.3%) 11 (9.1%) 15 (13.8%) 0.26
3 204 (88.7%) 110 (90.9%) 94 (86.2%)
Multiple tumours
Yes 46 (20.0%) 20 (16.5%) 26 (23.9%) 0.21
No 183 (79.6%) 101 (83.5%) 82 (75.2%)
Unknown 1 (0.4%) 0 (0.0%) 1 (0.9%)
Extent of tumour resection
Not resected/Biopsy 25 (10.9%) 18 (14.9%) 7 (6.4%) 0.03
Complete resection 123 (53.5%) 67 (55.4%) 56 (51.4%)
Incomplete resection 77 (33.5%) 32 (26.4%) 45 (41.3%)
Resected (extent unknown) 2 (0.9%) 1 (0.8%) 1 (0.9%)
Unknown 3 (1.3%) 3 (2.5%) 0 (0.0%)
Tumour size group
o30mm 49 (21.3%) 31 (25.6%) 18 (16.5%) 0.07
430mm 105 (45.7%) 47 (38.8%) 58 (53.2%)
Unknown 76 (33.0%) 43 (35.5%) 33 (30.3%)
Residual mass post resection
Yes 67 (29.1%) 33 (27.3%) 34 (31.2%) 0.09
No 151 (65.7%) 78 (64.5%) 73 (67.0%)
Unknown 12 (5.2%) 10 (8.3%) 2 (1.8%)
Haemoglobin, gdl1
N 230 121 109 0.20
Median (Q25–Q75) 12.9 (11.9–14.1) 12.8 (11.8–13.7) 13.3 (11.9–14.2)
Min–Max 8–16.7 8.5–16.7 8–16.4
WBC, 109 per l
N 230 121 109 0.90
Median (Q25–Q75) 7 (5.6–8.8) 7 (5.4–8.8) 7.1 (5.7–8.8)
Min–Max 1.9–24 1.9–23.2 1.9–24
Glomerular filtration rate (mlmin1 per 1.73m2)
N 215 118 97 0.28
Median (Q25–Q75) 64 (49–80) 64.5 (52–80) 63 (48–77)
Min–Max 28–156 29–140 28–156
Radiotherapy randomisation
stRT 43 (18.7%) 20 (16.5%) 23 (21.1%) 0.50
RHDVRT 35 (15.2%) 21 (17.4%) 14 (12.8%)
Elective stRT 152 (66.1%) 80 (66.1%) 72 (66.1%)
Radiotherapy treatment
55Gy/20F 74 (32.2%) 39 (32.2%) 35 (32.1%) 0.98
64Gy/32F 156 (67.8%) 82 (67.8%) 74 (67.9%)
Neoadjuvant therapy received
No 159 (69.1%) 84 (69.4%) 75 (68.8%) 0.92
Yes 71 (30.9%) 37 (30.6%) 34 (31.2%)
Necrosis
Absent 142 (61.7%) 73 (60.3%) 69 (63.3%) 0.64
Present 88 (38.3%) 48 (39.7%) 40 (36.7%)
Muscle invasive BC (as per central review)
Noc 70 (30.4%) 36 (29.8%) 34 (31.2%) 0.81
Yes 160 (69.6%) 85 (70.2%) 75 (68.8%)
Concurrent Cis (as per central review)
No 185 (80.4%) 98 (81.0%) 87 (79.8%) 0.82
Yes 45 (19.6%) 23 (19.0%) 22 (20.2%)
Q1: Lower quartile, 25% percentile, Q3: Upper quartile, 75% percentile.
aP-value: for categorical variables, w2-test; for continuous variables, non-parametric Kruskall–Wallis rank test, except for Haemoglobin, t-test.
bThis tumour was deemed to be pathological stage T1, but radiologic staging confirmed the tumour as T3. Therefore, the patient was not considered to be ineligible for the trial. Analysed as
T3.
cAll patients were confirmed as MIBC within the BC2001 study, however, not all tissue blocks were available for central review.
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where necrosis was absent, 5-year OS was 39.5% for the
chemoradiotherapy group and 34.6% for radiotherapy alone
(HR¼ 0.96, 95% CI 0.63–1.47, log-rank P¼ 0.92). In 88 patients
with tumour necrosis, five-year OS was 51.8% for the chemor-
adiotherapy group and 34.6% for radiotherapy alone (HR¼ 0.68,
95% CI 0.40–1.17, log-rank P¼ 0.16). However, there was no
interaction between treatment and necrosis in either univariable
(P¼ 0.32) or multivariable (Table 3, predictive model, P¼ 0.56)
analyses. As for LRC, necrosis had no prognostic significance for
OS in either univariable or multivariable analyses (Table 3,
univariable and prognostic models; Figure 3C). Significant adverse
prognostic factors in the 230 patient cohort were poor performance
status, residual mass after resection and low haemoglobin. The
presence of necrosis also had no prognostic significance when the
radiotherapy only arm was analysed for OS (Figure 3D).
DISCUSSION
Necrosis was not associated with survival or predictive of outcome
following chemoradiotherapy with MMC and 5-FU. Previous
studies of lower and upper tract transitional cell carcinoma showed
HR (95% CI) = 0.60 (0.35–1.03)
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Figure 2. Kaplan–Meier curves for locoregional control (A, B) and overall survival (C, D) after radiotherapy (RT) or chemoradiotherapy (RTþCT) and
stratified according to absence (A, C) or presence (B, D) of necrosis. Test for interaction between necrosis and treatment yielded unadjusted
P-value of 0.467 (locoregional control) and 0.0323 (overall survival).
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necrosis to be strongly associated with prognosis (Ord et al, 2007;
Zigeuner et al, 2010; Eustace et al, 2013; Soave et al, 2015). This
discrepancy in findings could be accounted for by tumour
heterogeneity with a single section taken at random not being
indicative of the whole transurethral resection of bladder tumour
specimen. Compared with the BCON study where 121 out of 231
(52%) had necrosis, fewer patients in the BC2001 study (38%) had
necrosis present as defined by a specialist uro-pathologist. This
possible explanation is supported by differences in the stage
distribution between the two studies where the BCON cohort had a
greater proportion of T3 and T4 tumours than seen in the BC2001
cohort. These results may suggest that necrosis is an important
prognostic factor in patients with more advanced disease where
hypoxia could be more prevalent. A further explanation as to why
necrosis may not be prognostic in this study could be that TURBT
or the use of neoadjuvant chemotherapy may have had an impact
on the results compared with those of previous studies in the
literature. For example, in the BC2001 necrosis cohort 11% were
not resected (Table 1) in comparison with 27% in the BCON
necrosis cohort (Eustace et al, 2013). The higher level of complete
resection in BC2001 (54 vs 39% for BCON) might reduce the
impact of necrosis as an adverse prognostic factor for radiotherapy
outcomes. Similarly, 31% of BC2001 (Table 1) vs 0% of BCON
(Eustace et al, 2013) patients had neoadjuvant chemotherapy
following TURPT and prior to radiotherapy. It is worth noting that
the same experienced pathologist scored both the BCON
and BC2001 cohorts for necrosis, which reduces possible observer
bias.
Although hypoxia has been shown to be an important
prognostic factor in MIBC (Hoskin et al, 2003; Palit et al, 2005;
Ord et al, 2007; Hunter et al, 2014), it is difficult to measure
directly using Eppendorf electrodes due to issues of access. Our
group (Eustace et al, 2013) has previously shown that coagulative
tumour necrosis, thought to be specific to tumour hypoxia, is an
easily measurable histopathological parameter which can be used
to predict benefit from hypoxia-modifying treatment using CON.
We have also shown that the predictive power of necrosis is not
improved by the addition of immunohistochemical scoring with
hypoxia-associated proteins CAIX, GLUT-1 or HIF-1a (Hunter
et al, 2014).
Although BCON is an accepted standard of care for bladder
preserving treatment for MIBC, concurrent chemotherapy is more
commonly used as a radiosensitiser. The BC2001 trial randomised
patients with MIBC between radiotherapy alone and radiotherapy
with MMC and 5-FU resulting in an improvement in locoregional
control at 2 years from 54 to 67% (James et al, 2012). MMC is a
weak bioreductive agent resulting in DNA crosslinks once inside
the cell. 5-FU is a thymidylate synthase (TS) inhibitor. Inhibition
of this enzyme blocks synthesis of the pyrimidine thymidine, which
is a nucleoside essential for DNA replication. These drugs have a
different primary mechanism of action compared with CON,
which act by improving the oxygenation of tissues by increasing
Table 2. Prognostic and predictive value of necrosis for locoregional control
Univariable models Multivariable model (prognostic) Multivariable model (prognostic)
N HR 95% CI P-value N HR 95% CI P-value N HR 95% CI P-value
Sex
Male (ref) 183 1.00 172 1.00 172 1.00
Female 47 1.06 0.63 1.79 0.83 46 1.21 0.70 2.08 0.50 46 1.22 0.71 2.10 0.48
Age (years) 230 1.00 0.97 1.03 0.79 218 1.00 0.97 1.03 0.80 218 1.00 0.97 1.03 0.80
WHO performance status
0 (ref) 146 1.00 142 1.00 142 1.00
1–2 84 1.27 0.82 1.97 0.28 76 1.37 0.86 2.19 0.19 76 1.36 0.85 2.17 0.21
Stage
2 (ref) 202 1.00 191 1.00 191 1.00
3–4 28 2.08 1.20 3.58 0.009 27 1.86 1.00 3.47 0.05 27 1.86 1.00 3.45 0.05
Tumour size
o30 mm (ref) 49 1.00 46 1.00 46 1.00
X30 mm 105 1.59 0.86 2.92 0.14 102 1.30 0.67 2.52 0.44 102 1.30 0.67 2.52 0.44
Unknown 76 1.69 0.90 3.19 0.10 70 1.67 0.85 3.28 0.14 70 1.69 0.85 3.34 0.13
Residual mass after resection*
No (ref) 151 1.00 151 1.00 151 1.00
Yes 67 2.32 1.49 3.60 o0.001 67 1.96 1.19 3.22 0.008 67 1.94 1.18 3.20 0.01
Cis
Absent (ref) 185 1.00 175 1.00 175 1.00
Present 45 0.80 0.45 1.42 0.45 43 0.87 0.48 1.59 0.65 43 0.87 0.48 1.58 0.64
Necrosis
Absent (ref) 142 1.00 134 1.00 Included in interaction below
Present 88 0.86 0.55 1.34 0.50 84 0.89 0.55 1.44 0.65
Treatment
Radiotherapy (ref) 109 1.00 107 1.00 Included in interaction below
Chemoradiotherapy 121 0.53 0.34 0.82 0.005 111 0.51 0.32 0.81 0.004
Necrosis absent: treatment
Radiotherapy Not applicable, model without interaction 68 1.00
Chemoradiotherapy 66 0.55 0.31 0.98 0.04
Necrosis present: treatment
Radiotherapy Not applicable, model without interaction 39 1.00
Chemoradiotherapy 45 0.46 0.21 0.99 0.05
Hazard ratios for all covariates in the models are included. Univariable models present unadjusted estimates for necrosis treatment, and all other prognostic factors; Multivariable model
(prognostic) provides the prognostic value for necrosis adjusted by other relevant factors; Multivariable model (predictive) model provides predictive value for necrosis adjusted for other
important factors (test for interaction necrosis:treatment, adjusted P-value 0.71).
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the oxygen tension and improving vasodilatation. The absence of a
significant association between necrosis and response to MMC and
5-FU confirms our hypothesis that necrosis may only be suitable
for selecting MIBC patients with significantly hypoxic tumours,
which would benefit from hypoxia modification. Future work will
involve looking at potential biomarkers associated with the mode
of action of MMC and 5-FU to try and select patient groups who
specifically benefit from this chemoradiotherapy regimen.
A limitation of the study was that samples were only available
for 64% of the patients enroled in the BC2001 trial. Although there
were no statistically significant differences in outcomes for patients
for whom samples were or were not available (Supplementary
Figure S2), there was a trend for better OS in patients with samples.
A second limitation, related to the first, was that the study may be
underpowered and weakened by small sample sizes for sub-groups.
For example, in Figure 2 the benefit of giving chemotherapy with
radiotherapy appears stronger in patients with necrosis present.
Further work to validate our results is required with the issue of
necrosis being a prognostic factor for MIBC still not resolved. If
necrosis is validated as a predictive factor for response to hypoxia
modification and radical radiotherapy for MIBC, then it could be
used to select patients who are likely to benefit from CON. The
HR (95% CI) = 0.86 (0.55–1.34)
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Figure 3. Investigation of necrosis as a prognostic factor for locoregional control in all 230 patients (A) and in 109 patients receiving radiotherapy
only (B), and for overall survival in all 230 patients (C) and in 109 patients receiving radiotherapy alone (D).
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conclusion from the study reported here is that tumour necrosis is
neither predictive nor prognostic, and therefore MMC/5-FU is an
appropriate radiotherapy-sensitising treatment independent of
necrosis status.
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